Repligen Corp. diskutieren
Repligen Corp.
WKN: 870980 / Symbol: RGEN / Name: Repligen Corp / Aktie / Pharmazeutika / Mid Cap /
155,15 €
-4,64 %
Repligen Co. (NASDAQ: RGEN) was upgraded by analysts at Royal Bank of Canada from a "sector perform" rating to an "outperform" rating.
Ratings data for RGEN provided by MarketBeat
Repligen Co. (NASDAQ: RGEN) had its price target raised by analysts at Stephens from $180.00 to $200.00. They now have an "overweight" rating on the stock.
Ratings data for RGEN provided by MarketBeat
Repligen Co. (NASDAQ: RGEN) had its price target raised by analysts at Royal Bank of Canada from $157.00 to $195.00. They now have an "outperform" rating on the stock.
Ratings data for RGEN provided by MarketBeat
Repligen Co. (NASDAQ: RGEN) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $191.00 price target on the stock.
Ratings data for RGEN provided by MarketBeat
Repligen Co. (NASDAQ: RGEN) had its price target lowered by analysts at JPMorgan Chase & Co. from $200.00 to $180.00. They now have an "overweight" rating on the stock.
Ratings data for RGEN provided by MarketBeat
Repligen Co. (NASDAQ: RGEN) had its price target lowered by analysts at KeyCorp from $240.00 to $210.00. They now have an "overweight" rating on the stock.
Ratings data for RGEN provided by MarketBeat
Repligen Co. (NASDAQ: RGEN) had its price target lowered by analysts at Royal Bank of Canada from $207.00 to $200.00. They now have an "outperform" rating on the stock.
Ratings data for RGEN provided by MarketBeat
Repligen Co. (NASDAQ: RGEN) had its price target lowered by analysts at Stifel Nicolaus from $200.00 to $165.00. They now have a "buy" rating on the stock.
Ratings data for RGEN provided by MarketBeat
Repligen Co. (NASDAQ: RGEN) had its price target lowered by analysts at UBS Group AG from $210.00 to $170.00. They now have a "buy" rating on the stock.
Ratings data for RGEN provided by MarketBeat
Repligen Co. (NASDAQ: RGEN) had its price target raised by analysts at JPMorgan Chase & Co. from $170.00 to $210.00. They now have an "overweight" rating on the stock.
Ratings data for RGEN provided by MarketBeat
Repligen Co. (NASDAQ: RGEN) had its price target raised by analysts at KeyCorp from $210.00 to $220.00. They now have an "overweight" rating on the stock.
Ratings data for RGEN provided by MarketBeat
Repligen Co. (NASDAQ: RGEN) had its price target raised by analysts at Stifel Nicolaus from $165.00 to $207.00. They now have a "buy" rating on the stock.
Ratings data for RGEN provided by MarketBeat
Repligen Co. (NASDAQ: RGEN) had its price target lowered by analysts at JPMorgan Chase & Co. from $230.00 to $200.00. They now have an "overweight" rating on the stock.
Ratings data for RGEN provided by MarketBeat
Neueste Beiträge
StockNews_com in Fortinet Inc. diskutieren